Windlas Biotech Limited - Asset Resilience Ratio
Windlas Biotech Limited (WINDLAS) has an Asset Resilience Ratio of 32.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Windlas Biotech Limited short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Windlas Biotech Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see WINDLAS current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Windlas Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Windlas Biotech Limited debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.61 Billion | 32.06% |
| Total Liquid Assets | Rs2.61 Billion | 32.06% |
Asset Resilience Insights
- Very High Liquidity: Windlas Biotech Limited maintains exceptional liquid asset reserves at 32.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Windlas Biotech Limited Industry Peers by Asset Resilience Ratio
Compare Windlas Biotech Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Windlas Biotech Limited (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Windlas Biotech Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 31.54% | Rs2.40 Billion ≈ $25.94 Million |
Rs7.60 Billion ≈ $82.24 Million |
-0.25pp |
| 2024-03-31 | 31.79% | Rs1.99 Billion ≈ $21.53 Million |
Rs6.26 Billion ≈ $67.72 Million |
+7.54pp |
| 2023-03-31 | 24.25% | Rs1.28 Billion ≈ $13.87 Million |
Rs5.29 Billion ≈ $57.21 Million |
-11.48pp |
| 2022-03-31 | 35.73% | Rs1.75 Billion ≈ $18.97 Million |
Rs4.91 Billion ≈ $53.10 Million |
+22.79pp |
| 2021-03-31 | 12.94% | Rs383.25 Million ≈ $4.14 Million |
Rs2.96 Billion ≈ $32.02 Million |
+6.27pp |
| 2020-03-31 | 6.67% | Rs225.86 Million ≈ $2.44 Million |
Rs3.38 Billion ≈ $36.61 Million |
-0.45pp |
| 2019-03-31 | 7.12% | Rs212.41 Million ≈ $2.30 Million |
Rs2.98 Billion ≈ $32.25 Million |
-0.76pp |
| 2018-03-31 | 7.88% | Rs228.53 Million ≈ $2.47 Million |
Rs2.90 Billion ≈ $31.35 Million |
-- |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more